📗 Cite This Artifact
Inclisiran for Lewy Body Disorders Trial
Inclisiran for Lewy Body Dementia Trial
Overview
Inclisiran (brand name: Leqvio®) is a small interfering RNA (siRNA) therapeutic originally developed for cardiovascular disease that is being investigated for potential use in Lewy body dementia (LBD). It works by silencing the PCSK9 gene to modify lipid metabolism, which may have implications for neurodegeneration through vascular mechanisms[@pcsk2023].
Clinical Trial Identifier: [NCT05669703](https://clinicaltrials.gov/study/NCT05669703)
| Field | Value |
|-------|-------|
| Phase | Phase 2 |
| Status | Ongoing |
| Drug | Inclisiran (Leqvio®) |
| Mechanism | PCSK9 gene silencing (siRNA) |
| Dosing | Subcutaneous injection |
| Patient Population | Patients with Lewy body dementia |
Background: Inclisiran
What is Inclisiran?
Inclisiran is a first-in-class siRNA therapeutic that:
- Targets PCSK9 (proprotein convertase subtilisin/kexin type 9) gene
- Administered via subcutaneous injection
- Provides long-lasting LDL cholesterol reduction (effective for 6+ months)
- Approved for cardiovascular disease treatment
siRNA Technology
Small interfering RNA (siRNA) drugs work through RNA interference (RNAi):
Inclisiran for Lewy Body Dementia Trial
Overview
Inclisiran (brand name: Leqvio®) is a small interfering RNA (siRNA) therapeutic originally developed for cardiovascular disease that is being investigated for potential use in Lewy body dementia (LBD). It works by silencing the PCSK9 gene to modify lipid metabolism, which may have implications for neurodegeneration through vascular mechanisms[@pcsk2023].
Clinical Trial Identifier: [NCT05669703](https://clinicaltrials.gov/study/NCT05669703)
| Field | Value |
|-------|-------|
| Phase | Phase 2 |
| Status | Ongoing |
| Drug | Inclisiran (Leqvio®) |
| Mechanism | PCSK9 gene silencing (siRNA) |
| Dosing | Subcutaneous injection |
| Patient Population | Patients with Lewy body dementia |
Background: Inclisiran
What is Inclisiran?
Inclisiran is a first-in-class siRNA therapeutic that:
- Targets PCSK9 (proprotein convertase subtilisin/kexin type 9) gene
- Administered via subcutaneous injection
- Provides long-lasting LDL cholesterol reduction (effective for 6+ months)
- Approved for cardiovascular disease treatment
siRNA Technology
Small interfering RNA (siRNA) drugs work through RNA interference (RNAi):
This is different from traditional small molecule drugs - siRNA can target previously "undruggable" genes.
Mechanism of Action in LBD
PCSK9 and Neurodegeneration
While primarily studied for cardiovascular applications, PCSK9 may play a role in neurodegeneration:
- PCSK9 expression in the brain
- Potential effects on [amyloid-beta](/proteins/amyloid-beta) metabolism
- Neuroinflammation modulation
- [Blood-brain barrier](/entities/blood-brain-barrier) (BBB) integrity
The Vascular Hypothesis in LBD
Lewy body dementia often involves:
- Cerebrovascular disease comorbidity
- Blood-brain barrier dysfunction
- Cerebral hypoperfusion
- White matter lesions
By improving vascular health through LDL reduction, inclisiran may:
- Improve cerebral blood flow
- Reduce vascular inflammation
- Protect neuronal function
- Slow disease progression
Trial Design
Study Objectives
Inclusion Criteria
- Diagnosis of dementia with Lewy bodies (DLB) or Parkinson's disease dementia (PDD)
- Stable background therapy
- Adequate liver and kidney function
Treatment Regimen
- Inclisiran subcutaneous injections
- Dosing schedule per protocol
- Monitoring for adverse effects
PCSK9 Biology and Cardiovascular Role
PCSK9 Overview
PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) is a serine protease that plays a crucial role in LDL cholesterol metabolism:
Normal Function:
- Secreted by hepatocytes
- Binds to LDL receptor (LDLR) on hepatocyte surface
- Promotes LDLR degradation in lysosomes
- Reduces LDLR recycling to cell surface
- Result: Increased plasma LDL cholesterol
- Gain-of-function mutations → familial hypercholesterolemia
- Loss-of-function mutations → lower LDL and reduced cardiovascular risk
- This validated PCSK9 as a therapeutic target
PCSK9-Targeting Therapies
Monoclonal Antibodies:
- Alirocumab (Praluent®)
- Evolocumab (Repatha®)
- Bind PCSK9 in circulation
- Require frequent dosing (bi-weekly)
- Direct hepatic delivery via GalNAc conjugation
- Silences PCSK9 gene expression
- Long-lasting effect (6+ months)
- Lower dosing frequency
Cardiovascular Outcomes Trial (ORION-4)
The pivotal trial establishing inclisiran's efficacy:
Study Design:
- Randomized, double-blind, placebo-controlled
- 16,000+ patients with atherosclerotic cardiovascular disease
- Primary endpoint: MACE (Major Adverse Cardiovascular Events)
- Significant LDL reduction (~50%)
- Reduced cardiovascular events
- Acceptable safety profile
Mechanism of Action in LBD
PCSK9 and Neurodegeneration
While primarily studied for cardiovascular applications, PCSK9 may play a role in neurodegeneration:
- PCSK9 expression in the brain[@sato2023]
- Potential effects on [amyloid-beta](/proteins/amyloid-beta) metabolism
- Neuroinflammation modulation
- [Blood-brain barrier](/entities/blood-brain-barrier) (BBB) integrity
PCSK9 in the Central Nervous System
Emerging research reveals PCSK9 has functions beyond hepatic cholesterol regulation:
Brain Expression:
- PCSK9 is expressed in neurons and glia
- Higher expression in AD and PD brain tissue
- Colocalizes with amyloid plaques and Lewy bodies
- Modulation of amyloid precursor protein (APP) processing
- Effects on tau phosphorylation
- Neuroinflammatory signaling
- Synaptic function regulation
The Vascular Hypothesis in LBD
Lewy body dementia often involves:
- Cerebrovascular disease comorbidity (50-70% of patients)[@shibata2022]
- Blood-brain barrier dysfunction
- Cerebral hypoperfusion
- White matter lesions
- Small vessel disease
By improving vascular health through LDL reduction, inclisiran may:
- Improve cerebral blood flow
- Reduce vascular inflammation
- Protect neuronal function
- Slow disease progression
Cerebral Small Vessel Disease
CSVD is a key contributor to cognitive decline in LBD:
Pathological Features:
- Lipohyalinosis of small vessels
- Fibrinoid necrosis
- Microaneurysms
- White matter hyperintensities on MRI
- Contributes to executive dysfunction
- Increases gait impairment
- Adds to parkinsonism
- Accelerates dementia progression
- Hypoperfusion → energy failure
- BBB breakdown → protein extravasation
- Microinfarcts → focal deficits
Trial Design
Study Objectives
Inclusion Criteria
- Diagnosis of dementia with Lewy bodies (DLB) or Parkinson's disease dementia (PDD)
- Stable background therapy
- Adequate liver and kidney function
Outcome Measures
Primary Endpoints:
- Adverse events and serious adverse events
- Discontinuation rate
- Laboratory abnormalities
- Change in plasma PCSK9 levels
- Change in LDL cholesterol
- Change in inflammatory markers (IL-6, CRP)
- Cognitive assessment (MDS-UPDRS part I, MoCA)
- MRI brain volumetry
- Cerebral blood flow measurements
- CSF biomarkers (α-synuclein, tau, Aβ)
Trial Phases
Phase 1 (Completed):
- Pharmacokinetic assessment
- Dose selection
- Safety and tolerability in LBD population
- Biomarker validation
- Signal detection for cognitive outcomes
- Large-scale efficacy trial
- Cognitive and functional endpoints
Clinical Significance
Why Repurpose Inclisiran for LBD?
This trial represents a novel approach to LBD treatment:
Advantages of siRNA Approach
Efficiency:
- Single dose provides months of effect
- Improved adherence
- Steady pharmacological effect
- Gene-specific targeting
- Minimal off-target effects
- Precise mechanism
- Novel therapeutic class for neurodegeneration
- Potential for combination approaches
- Addresses "undruggable" targets
Comparison: LBD Treatment Landscape
| Drug/Approach | Mechanism | Status |
|--------------|-----------|--------|
| Inclisiran | PCSK9 siRNA | Phase 2 |
| [Donepezil](/entities/donepezil)/Rivastigmine | Cholinesterase inhibition | Approved |
| Memantine | NMDA antagonism | Approved |
| Levodopa | Dopamine replacement | Approved (for PD) |
| Duvyuatide | Alpha-synuclein aggregation inhibitor | Phase 2 |
| Blenrep | Anti-amyloid antibody | Phase 3 |
Challenges and Considerations
- Blood-brain barrier: siRNA may have limited CNS penetration
- Target relevance: PCSK9's role in LBD is not fully established
- Biomarker validation: Surrogate endpoints need validation
- Vascular vs. Direct: Unclear if benefit is vascular only
Lipid Metabolism and Neurodegeneration
Cholesterol in the Brain
The brain has distinct cholesterol metabolism:
CNS Cholesterol:
- Separate from peripheral pool
- Synthesized locally by astrocytes and neurons
- Essential for myelin, synaptic function
- Cannot cross BBB from circulation
- Altered membrane fluidity
- Impaired synaptic transmission
- Myelin abnormalities
- Increased oxidative stress
LDL and Alzheimer's Disease
Vascular contributions to AD are well-established:
Epidemiological:
- Mid-life hypercholesterolemia → AD risk
- Statins may reduce AD risk
- Lipid-lowering therapy associated with reduced incidence
- Amyloid processing linked to cholesterol
- Cholesterol-rich membrane domains (rafts)
- Vascular amyloid deposition (CAA)
LDL and Parkinson's Disease
Similar vascular links in PD:
- Lower LDL associated with faster progression
- Statin use associated with reduced PD risk
- Vascular parkinsonism overlap
Implications for LBD
LBD shares features with both AD and PD:
- Amyloid and α-synuclein pathology
- Significant vascular comorbidity
- Cholinergic deficits
Lipid-lowering may provide:
- Reduced cerebrovascular burden
- Direct neuroprotective effects
- Improved cerebral perfusion
siRNA Technology Platform
How siRNA Works
RNA Interference (RNAi):
GalNAc Delivery
Targeted Hepatic Delivery:
- N-acetylgalactosamine (GalNAc) conjugates
- Binds to asialoglycoprotein receptor on hepatocytes
- Enables efficient liver accumulation
- Reduces off-target effects
- Liver-targeted delivery
- Reduced systemic exposure
- Lower doses required
- Improved safety margin
Comparison to Other Approaches
| Feature | siRNA (Inclisiran) | Monoclonal Antibody | Small Molecule |
|---------|------------------|-------------------|----------------|
| Target | mRNA | Protein | Protein |
| Duration | 6+ months | 2 weeks | Daily |
| Delivery | Subcutaneous | Subcutaneous | Oral |
| Specificity | High | High | Moderate |
| CNS Penetration | Limited | Limited | Variable |
Future Directions
Biomarker Development
Needed Biomarkers:
- Peripheral PCSK9 as CNS proxy
- Neurofilament light chain (NfL)
- α-synuclein seeding assays
- Neuroimaging markers
Combination Approaches
Potential Combinations:
- Inclisiran + cholinesterase inhibitors
- Inclisiran + α-synuclein-targeted therapy
- Inclisiran + disease-modifying antibodies
Personalized Medicine
Patient Selection:
- Vascular phenotype emphasis
- Lipid profile optimization
- Genetic stratification (APOE, PCSK9 variants)
Clinical Trial Protocol Details
Study Design Features:
- Randomized, double-blind, placebo-controlled
- Parallel-group design with 1:1 allocation
- 52-week treatment period
- 24-week follow-up for safety
- Approximately 80-100 participants
- 90% power to detect 30% reduction in LDL
- Stratified by baseline cholesterol and age
- Adverse event collection throughout study
- Periodic liver function testing
- Lipid panel monitoring
- Neurological assessment
Pharmacoeconomics
Cost Considerations:
- Inclisiran costs approximately $6,500/year
- Cardiovascular trials show cost-effectiveness
- LBD burden similar to AD (~$100K/year)
- Potential to reduce institutionalization
- Long-lasting effect reduces administration burden
- Potential to delay dementia progression
- Cardiovascular benefits in mixed pathology
- Reduced caregiver burden
Cardiovascular Efficacy Data
ORION-9, ORION-10, and ORION-11 Trials
ORION-9 (Heterozygous Familial Hypercholesterolemia):
- 482 patients with HeFH
- 48% LDL reduction at 17 months
- Well-tolerated with no discontinuations
- Over 3,000 patients with atherosclerotic cardiovascular disease
- LDL reduction of ~50%
- Sustained effect over 18+ months
- 16,000+ patients
- Ongoing to assess cardiovascular events
- Expected completion 2024-2025
Real-World Evidence
Observational Studies:
- Integrated delivery systems showing adherence benefit
- Specialty pharmacy data demonstrating persistence
- Cardiovascular registry follow-up
- Large-scale safety monitoring
- Rare adverse event detection
- Effectiveness in diverse populations
Vascular Mechanisms in LBD
Cerebral Small Vessel Disease Pathophysiology
Arteriolosclerosis:
- Hyaline deposition in vessel walls
- Smooth muscle cell loss
- Reduced autoregulation
- Fibrinoid necrosis
- Lipid accumulation
- Microaneurysm formation
- Aβ deposition in vessel walls
- Smooth muscle degeneration
- Increased hemorrhage risk
Blood-Brain Barrier Dysfunction
Mechanisms:
- Tight junction disruption
- Pericyte dysfunction
- Astrocyte end-foot damage
- More pronounced than in AD
- Correlates with white matter lesions
- Associated with cognitive decline
Neurovascular Unit
Components:
- Endothelial cells
- Pericytes
- [Astrocytes](/cell-types/astrocytes) Neurons
- Impaired coupling
- Reduced clearance
- Increased inflammation
siRNA in Neurodegeneration
Clinical Pipeline
Alnylam Programs:
- ATTR amyloidosis (approved)
- Hepatic porphyrias (approved)
- CNS-targeted programs in development
- Ionis ASOs
- Dicerna RNAi
- Arrowhead RNAi
Challenges for CNS Delivery
Barriers:
- Blood-brain barrier
- Peripheral vs CNS delivery
- Target engagement verification
- Focused ultrasound
- AAV vectors
- Exosome delivery
Future Directions in Neurodegeneration
Gene-Specific Silencing:
- Huntington's disease (HTT)
- SOD1 ALS
- C9orf72 ALS
- Simultaneous silencing of multiple genes
- Combination with other modalities
Current Status and Future Directions
Trial Status
Phase 2 Progress:
- Enrollment ongoing
- Safety monitoring active
- Preliminary biomarker data expected 2026
- Phase 2 completion: 2027
- Phase 3 decision: 2028
- Potential approval: 2030+
Broader Implications
If Successful:
- Paradigm shift for LBD treatment
- Vascular pathway validation
- siRNA application in dementia
- Refines understanding of LBD biology
- Informs future vascular targeting
- Guides patient selection
Patient Perspective
Caregiver Considerations
Daily Management:
- LBD requires 24/7 supervision in advanced stages
- Fluctuating cognition creates unpredictable needs
- Behavioral symptoms challenging to manage
- Multiple daily medications common
- Frequent medical appointments
- Therapy and rehabilitation sessions
- Semi-annual dosing simplifies regimen
- Cardiovascular protection
- Potential to slow progression reduces care burden
Quality of Life Impact
Domains Affected:
- Physical function (gait, fall risk)
- Cognition (memory, executive function)
- Behavior (hallucinations, depression)
- Autonomic (orthostasis, constipation)
- Maintain independence
- Reduce hospitalizations
- Support community living
- Improve caregiver wellbeing
Competitive Landscape
Other Lipid-Targeting Approaches
Statins:
- Widely used, well-characterized
- Mixed evidence in dementia
- Generic, low cost
- No large-scale LBD trials
- Alirocumab, Evolocumab
- Frequent dosing (bi-weekly)
- Approved for cardiovascular disease
- Not studied in LBD
- ATP citrate lyase inhibitor
- Oral, once-daily
- Lower LDL modestly
- Limited CNS data
Comparison Summary
| Approach | Dosing | LDL Reduction | LBD Data | Cost |
|----------|--------|---------------|----------|------|
| Inclisiran | 6 months | ~50% | Ongoing | $$$ |
| Statins | Daily | 20-55% | Mixed | $ |
| PCSK9 mAbs | 2 weeks | ~60% | None | $$$$ |
| Bempedoic Acid | Daily | ~17% | None | $$ |
Conclusion
The inclisiran LBD trial represents an innovative approach to treating dementia by targeting vascular contributions to neurodegeneration. By repurposing a proven cardiovascular therapy with a novel mechanism, this trial addresses the significant vascular component often present in LBD pathophysiology.
Key aspects of this trial:
- First siRNA therapeutic evaluated in LBD
- Targets PCSK9 for lipid-lowering
- Leverages vascular hypothesis
- Builds on cardiovascular safety data
The trial's success would establish a new therapeutic paradigm in dementia care, recognizing the importance of vascular health in neurodegenerative diseases. Even negative results will advance our understanding of LBD biology and guide future development of vascular-targeted approaches.
Related Pages
- [Lewy Body Dementia](/diseases/lewy-body-dementia) - Target disease
- [Parkinson's Disease Dementia](/diseases/parkinson-s-disease-dementia) - Related condition
- [Inclisiran](/entities/inclisiran) - Drug entity
- [PCSK9](/proteins/pcsk9) - Target protein
- [siRNA Therapeutics](/technologies/sirna-therapeutics) - Drug class
- [Cerebral Vasculature](/mechanisms/cerebral-vascular-function) - Vascular mechanisms
External Links
- [ClinicalTrials.gov: NCT05669703](https://clinicaltrials.gov/study/NCT05669703)
- [Leqvio (Inclisiran) Information](https://www.leqvio.com/)
- [RNAi Therapeutics Society](https://www.rnai.org/)
See Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Vascular Dementia](/diseases/vascular-dementia)
- [Cholesterol Metabolism](/mechanisms/cholesterol-metabolism)
References
▸Metadataorigin_type: v1_polymorphic_backfill
| slug | clinical-trials-inclisiran-lewy-bodies |
| kg_node_id | None |
| entity_type | clinical |
| origin_type | v1_polymorphic_backfill |
| source_table | wiki_pages |
| wiki_page_id | wp-ef32a7deb855 |
| __merged_from | {'merged_at': '2026-05-13', 'unprefixed_id': 'clinical-trials-inclisiran-lewy-bodies'} |
| _schema_version | 1 |
No provenance edges found
Use ?embed=1 to load the artifact without SciDEX chrome — suitable for iframing into wiki pages or external sites.
<iframe src="http://scidex.ai/artifact/wiki-clinical-trials-inclisiran-lewy-bodies?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>
[Inclisiran for Lewy Body Disorders Trial](http://scidex.ai/artifact/wiki-clinical-trials-inclisiran-lewy-bodies)
http://scidex.ai/artifact/wiki-clinical-trials-inclisiran-lewy-bodies